SCHEMBL607506

SCHEMBL607506

O=C(O)C1=CN2C=COc3cccc(c32)C1

nearest known ligand 0.32

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
NOTUM Q6P988 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7262363 0.88 PARP1 (0.31)
SCHEMBL7210084 0.78
SCHEMBL6780549 0.75 GAA (0.32)
SCHEMBL2638362 0.74
SCHEMBL28414326 0.71 NOTUM (0.31) NOTUM
SCHEMBL9227676 0.70 GAA (0.33) NOTUM
SCHEMBL9273390 0.69 MCL1 (0.39) NOTUM
Hydrochloric Acid SCHEMBL10435581 0.69 GAA (0.33)
SCHEMBL8183764 0.68
SCHEMBL11202182 0.66 NOTUM (0.39) NOTUM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9353218-B2 Kit for multifunctional compounds forming crosslinked biomaterials ANGIOTECH PHARMACEUTICALS, INC. 2016-05-31 US disclosed
US-20130289235-A1 MULTIFUNCTIONAL COMPOUNDS FOR FORMING CROSSLINKED BIOMATERIALS AND METHODS OF PREPARATION AND USE ANGIOTECH PHARMACEUTICALS, INC. (CA) 2013-10-31 US disclosed
US-8486437-B2 Multifunctional compounds for forming crosslinked biomaterials and methods of preparation and use ANGIOTECH PHARMACEUTICALS (US), INC. (US) 2013-07-16 US disclosed
US-8481073-B2 Compositions and systems for forming crosslinked biomaterials and associated methods of preparation and use ANGIODEVICE INTERNATIONAL GMBH (CH) 2013-07-09 US disclosed
US-8460708-B2 Compositions and systems for forming crosslinked biomaterials and associated methods of preparation and use ANGIODEVICE INTERNATIONAL GMBH (CH) 2013-06-11 US disclosed
US-20130012683-A1 MULTIFUNCTIONAL COMPOUNDS FOR FORMING CROSSLINKED BIOMATERIALS AND METHODS OF PREPARATION AND USE ANGIOTECH PHARMACEUTICALS (US), INC. (US) 2013-01-10 US disclosed
US-8303973-B2 Multifunctional compounds for forming crosslinked biomaterials and methods of preparation and use ANGIOTECH PHARMACEUTICALS (US), INC. (US) 2012-11-06 US disclosed
EP-1708694-B1 COMPOSITIONS AND METHODS FOR TREATING CONTRACTURE ANGIOTECH INT AG (CH) 2012-07-11 EP disclosed
US-20120052040-A1 POLYMER COMPOSITIONS AND METHODS FOR THEIR USE ANGIOTECH INTERNATIONAL AG (CH) 2012-03-01 US disclosed
US-20120041481-A1 COMPOSITIONS AND SYSTEMS FOR FORMING CROSSLINKED BIOMATERIALS AND ASSOCIATED METHODS OF PREPARATION AND USE ANGIODEVICE INTERNATIONAL GMBH (CH) 2012-02-16 US disclosed
US-20050152945-A1 Soft tissue implants and anti-scarring agents ANGIOTECH INTERNATIONAL AG (CH) 2005-07-14 US disclosed
US-20050149157-A1 Electrical devices and anti-scarring agents ANGIOTECH INTERNATIONAL AG (CH) 2005-07-07 US disclosed
US-20050149158-A1 Medical implants and anti-scarring agents ANGIOTECH INTERNATIONAL AG (CH) 2005-07-07 US disclosed
US-20050149080-A1 Medical implants and anti-scarring agents ANGIOTECH INTERNATIONAL AG (CH) 2005-07-07 US disclosed
US-20050143817-A1 Medical implants and anti-scarring agents ANGIOTECH INTERNATIONAL AG (CH) 2005-06-30 US disclosed
US-20050142162-A1 Soft tissue implants and anti-scarring agents ANGIOTECH INTERNATIONAL AG (CH) 2005-06-30 US disclosed
WO-2005051452-A2 POLYMER COMPOSITIONS AND METHODS FOR THEIR USE ANGIOTECH INTERNATIONAL AG (CH) 2005-06-09 WO disclosed
WO-2005051316-A2 POLYMER COMPOSITIONS AND METHODS FOR THEIR USE ANGIOTECH INTERNATIONAL AG (CH) 2005-06-09 WO disclosed
WO-2005051444-A2 SOFT TISSUE IMPLANTS AND ANTI-SCARRING AGENTS ANGIOTECH INTERNATIONAL AG (CH) 2005-06-09 WO disclosed
WO-2005051232-A2 SOFT TISSUE IMPLANTS AND ANTI-SCARRING AGENTS ANGIOTECH INTERNATIONAL AG (CH) 2005-06-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050142162-A1 Soft tissue implants and anti-scarring agents MMP1, COL2A1, FN1 NOTUM 1052/4885
US-20120052040-A1 POLYMER COMPOSITIONS AND METHODS FOR THEIR USE COL2A1, COL14A1, COL1A1 NOTUM 2704/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.